Literature DB >> 12079390

Decreased thermodynamic stability as a crucial factor for familial amyloidotic polyneuropathy.

Tara Nath Niraula1, Katsuki Haraoka, Yukio Ando, Hua Li, Hiroaki Yamada, Kazuyuki Akasaka.   

Abstract

A single mutation in the wild-type transthyretin (WT TTR) such as V30M causes a familial amyloidotic polyneuropathy disease. Comparison of the three-dimensional crystal structures of WT and V30M does not tell much about the reason. High-pressure NMR revealed that at neutral pH both WT and V30M exist as equilibrium between the native tetramer and the dissociated/unfolded monomer. The native tetramer is highly stable in WT (deltaG(0)=104 kJ/mol at 37 degrees C, pH 7.1), but the stability is significantly reduced in V30M (deltadeltaG(0)=-18 kJ/mol), increasing the fraction of the unfolded monomer by a 1000-fold. Significant reduction of thermodynamic stability of WT TTR by mutation could be a crucial factor for familial amyloidotic polyneuropathy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079390     DOI: 10.1016/S0022-2836(02)00425-4

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  13 in total

1.  The pH-dependent stability of wild-type and mutant transthyretin oligomers.

Authors:  S Skoulakis; J M Goodfellow
Journal:  Biophys J       Date:  2003-05       Impact factor: 4.033

2.  Pressure-dissociable reversible assembly of intrinsically denatured lysozyme is a precursor for amyloid fibrils.

Authors:  Tara N Niraula; Takashi Konno; Hua Li; Hiroaki Yamada; Kazuyuki Akasaka; Hideki Tachibana
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

3.  Resolution of the effects induced by W → F substitutions on the conformation and dynamics of the amyloid-forming apomyoglobin mutant W7FW14F.

Authors:  Giuseppe Infusini; Clara Iannuzzi; Silvia Vilasi; Leila Birolo; Daniela Pagnozzi; Piero Pucci; Gaetano Irace; Ivana Sirangelo
Journal:  Eur Biophys J       Date:  2012-06-22       Impact factor: 1.733

4.  Amyloid fibril formation can proceed from different conformations of a partially unfolded protein.

Authors:  Martino Calamai; Fabrizio Chiti; Christopher M Dobson
Journal:  Biophys J       Date:  2005-09-16       Impact factor: 4.033

5.  Fourier transform infrared spectroscopy provides a fingerprint for the tetramer and for the aggregates of transthyretin.

Authors:  Yraima Cordeiro; Julia Kraineva; Marisa Carvalho Suarez; Anna Gabriella Tempesta; Jeffery W Kelly; Jerson L Silva; Roland Winter; Debora Foguel
Journal:  Biophys J       Date:  2006-05-12       Impact factor: 4.033

6.  Specific pathogen free conditions prevent transthyretin amyloidosis in mouse models.

Authors:  Seiya Inoue; Mika Ohta; Zhenghua Li; Gang Zhao; Yutaka Takaoka; Naomi Sakashita; Kazuhisa Miyakawa; Koji Takada; Hajime Tei; Misao Suzuki; Michio Masuoka; Yoshiyuki Sakaki; Kiyoshi Takahashi; Ken-Ichi Yamamura
Journal:  Transgenic Res       Date:  2008-03-21       Impact factor: 2.788

7.  The serum protein transthyretin as a platform for dimerization and tetramerization of antibodies and Fab fragments to enable target clustering.

Authors:  Kenneth W Walker; Ian N Foltz; Tina Wang; Hossein Salimi-Moosavi; Julie M Bailis; Fei Lee; Phillip An; Stephen Smith; Richele Bruno; Zhulun Wang
Journal:  J Biol Chem       Date:  2020-06-09       Impact factor: 5.157

Review 8.  RNA-targeting and gene editing therapies for transthyretin amyloidosis.

Authors:  Alberto Aimo; Vincenzo Castiglione; Claudio Rapezzi; Maria Franzini; Giorgia Panichella; Giuseppe Vergaro; Julian Gillmore; Marianna Fontana; Claudio Passino; Michele Emdin
Journal:  Nat Rev Cardiol       Date:  2022-03-23       Impact factor: 49.421

Review 9.  Differential effects of glycation on protein aggregation and amyloid formation.

Authors:  Clara Iannuzzi; Gaetano Irace; Ivana Sirangelo
Journal:  Front Mol Biosci       Date:  2014-09-02

10.  The N-terminal helix controls the transition between the soluble and amyloid states of an FF domain.

Authors:  Virginia Castillo; Fabrizio Chiti; Salvador Ventura
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.